MedImmune and Advaxis partner on immuno-oncology combination clnical trial
MedImmune announced it has entered into a clinical trial collaboration with Advaxis. The Phase I/II immunotherapy study will evaluate safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis’ lead cancer immunotherapy vaccine. July 22, 2014